The current state of pemetrexed in ovarian cancer

Bibliography

• Ferlay J, Shin HR, Bray F, et al. Globocan 2008 v1.2 cancer incidence and mortality worldwide. Iarc cancerbase no,10 (internet), lyon, france. In: International Agency for Research on Cancer. 2010. Available from: http://globocan.iarc.fr
   Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66
   PubMed Web of Science ®Google Scholar
• Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 2003;21(10 Suppl):149s-67s
   PubMedGoogle Scholar
• Tomao F, Panici PB, Frati L, Tomao S. Emerging role of pemetrexed in ovarian cancer. Expert Rev Anticancer Ther 2009;9(12):1727-35
   PubMed Web of Science ®Google Scholar
• Available from: www.cancerresearchuk.org
   Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. Oceans: a randomized, double-blind, placebo-controlled phase iii trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17):2039-45
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the icon4/ago-ovar-2.2 trial. Lancet 2003;361(9375):2099-106
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28(20):3323-9
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351(24):2519-29
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Ludovisi M, Lorusso D, et al. Phase iii trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26(6):890-6
   PubMed Web of Science ®Google Scholar
• Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95(1):1-8
   PubMed Web of Science ®Google Scholar
• Mutch DG, Orlando M, Goss T, et al. randomized phase iii trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25(19):2811-18
   PubMed Web of Science ®Google Scholar
• Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase iii study of the north-eastern german society of gynecological oncology ovarian cancer study group. J Clin Oncol 2008;26(19):3176-82
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Kristeleit RS. Optimal treatment for relapsing ovarian cancer. Ann Oncol 2010;21(Suppl 7):vii218-22
   PubMedGoogle Scholar
• Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 2013;19(5):961-8
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E HF, Weber B, Reuss A, et al. AURELIA Investigators: aurelia: a randomized phase iii trial evaluating bevacizumab (bev) plus chemotherapy (ct) for platinum (pt)-resistant recurrent ovarian cancer (oc). J Clin Oncol 2012;30(Suppl):abstract LBA5002
   Google Scholar
• Jackman CNA. Potential for α- folate receptor-targeted treatment for ovarian cancer. In: Kaye S, editor. Emerging therapeutic targets in ovarian cancer. Spring Science, New York, USA; 2011. p. 245-57
   Google Scholar
• Chen YL, Chang MC, Huang CY, et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 2012;6(3):360-9
   PubMed Web of Science ®Google Scholar
• Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of morab-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007;7:6
   PubMedGoogle Scholar
• Theti DS, Bavetsias V, Skelton LA, et al. Selective delivery of cb300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. Cancer Res 2003;63(13):3612-18
   PubMed Web of Science ®Google Scholar
• Leamon CP, Reddy JA, Vlahov IR, et al. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm 2007;4(5):659-67
   PubMedGoogle Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase iii study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21(14):2636-44
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589-97
   PubMed Web of Science ®Google Scholar
• Curtin NJ, Hughes AN. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol 2001;2(5):298-306
   PubMedGoogle Scholar
• Shih C, Chen VJ, Gossett LS, et al. Ly231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57(6):1116-23
   PubMed Web of Science ®Google Scholar
• Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002;29(6 Suppl 18):3-17
   PubMed Web of Science ®Google Scholar
• Zhao R, Babani S, Gao F, et al. The mechanism of transport of the multitargeted antifolate (mta) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res 2000;6(9):3687-95
   PubMed Web of Science ®Google Scholar
• Adjei AA. Pemetrexed (alimta), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004;10(12 Pt 2):4276s-80s
   PubMed Web of Science ®Google Scholar
• Westerhof GR, Schornagel JH, Kathmann I, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 1995;48(3):459-71
   PubMed Web of Science ®Google Scholar
• Rinaldi DA, Kuhn JG, Burris HA, et al. A phase i evaluation of multitargeted antifolate (mta, ly231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44(5):372-80
   PubMed Web of Science ®Google Scholar
• Rinaldi DA, Burris HA, Dorr FA, et al. Initial phase i evaluation of the novel thymidylate synthase inhibitor, ly231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995;13(11):2842-50
   PubMed Web of Science ®Google Scholar
• Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate ly231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase ii study. National cancer institute of canada clinical trials group. J Clin Oncol 1999;17(4):1194
   PubMed Web of Science ®Google Scholar
• Barnett CJ, Wilson TM, Grindey GB. Synthesis and antitumor activity of ly288601, the 5,6-dihydro analog of ly231514. Adv Exp Med Biol 1993;338:409-12
   PubMedGoogle Scholar
• Kano Y, Akutsu M, Tsunoda S, et al. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro. Cancer Chemother Pharmacol 2004;54(6):505-13
   PubMed Web of Science ®Google Scholar
• Kano Y, Akutsu M, Tsunoda S, et al. Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro. Oncol Res 2006;16(2):85-95
   PubMed Web of Science ®Google Scholar
• Kano Y, Tanaka M, Akutsu M, et al. Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro. Cancer Chemother Pharmacol 2009;64(6):1129-37
   PubMed Web of Science ®Google Scholar
• Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, ly231514, increases the cytotoxicity and antitumor activity of gemcitabine in ht29 colon carcinoma. Cancer Res 1999;59(15):3671-6
   PubMed Web of Science ®Google Scholar
• Morotti M, Valenzano Menada M, Venturini PL, et al. Pemetrexed disodium in ovarian cancer treatment. Expert Opin Investig Drugs 2012;21(4):437-49
   PubMed Web of Science ®Google Scholar
• Sehouli J, Camara O, Mahner S, et al. A phase-i trial of pemetrexed plus carboplatin in recurrent ovarian cancer. Cancer Chemother Pharmacol 2010;66(5):861-8
   PubMed Web of Science ®Google Scholar
• Chambers SK, Chow HH, Janicek MF, et al. Phase i trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clin Cancer Res 2012;18(9):2668-78
   PubMed Web of Science ®Google Scholar
• Hensley ML, Larkin J, Fury M, et al. A phase i trial of pemetrexed plus gemcitabine given biweekly with b-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clin Cancer Res 2008;14(19):6310-16
   PubMed Web of Science ®Google Scholar
• Richards DA, Loesch D, Vukelja SJ, et al. Phase i study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer. Invest New Drugs 2011;29(5):963-70
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Horowitz NS, Campos SM, et al. Phase ii study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2008;26(35):5761-6
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the ago-ovar, the ncic ctg, and the eortc gcg. J Clin Oncol 2006;24(29):4699-707
   PubMed Web of Science ®Google Scholar
• Sehouli J, Alvarez AM, Manouchehrpour S, et al. A phase ii trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol 2012;124(2):205-9
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Krasner CN, et al. Phase ii evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the gynecologic oncology group. J Clin Oncol 2009;27(16):2686-91
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase iii study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19(14):3312-22
   PubMed Web of Science ®Google Scholar
• Lund B, Hansen OP, Theilade K, et al. Phase ii study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86(20):1530-3
   PubMed Web of Science ®Google Scholar
• Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63(1):89-93
   PubMed Web of Science ®Google Scholar
• Vergote I, Calvert H, Kania M, et al. A randomised, double-blind, phase ii study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 2009;45(8):1415-23
   PubMed Web of Science ®Google Scholar
• Gasent Blesa JM, Alberola Candel V, Provencio Pulla M, et al. Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. Clin Transl Oncol 2009;11(1):35-40
   PubMed Web of Science ®Google Scholar
• Hagemann AR, Zighelboim I, Novetsky AP, et al. Phase ii trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012;30(Suppl):abstract 5013
   Google Scholar
• Schultz RM, Chen VJ, Bewley JR, et al. Biological activity of the multitargeted antifolate, mta (ly231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999;26(2 Suppl 6):68-73
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to nsclc histology: a review of two phase iii studies. Oncologist 2009;14(3):253-63
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51
   PubMed Web of Science ®Google Scholar
• Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger rna and protein levels for thymidylate synthase. Cancer 2006;107(7):1589-96
   PubMed Web of Science ®Google Scholar
• Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011;74(1):132-8
   PubMed Web of Science ®Google Scholar
• Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010;28(9):1534-9
   PubMed Web of Science ®Google Scholar
• Shimizu T, Nakanishi Y, Nakagawa Y, et al. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Anticancer Res 2012;32(10):4589-96
   PubMed Web of Science ®Google Scholar
• Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1(7):545-52
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (paramount): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13(3):247-55
   PubMed Web of Science ®Google Scholar
• Naumann RW SJ, Ghamande SA, Gabrail NY, et al. Precedent: a randomized phase ii trial comparing ec145 and pegylated liposomal doxorubicin (pld) in combination, versus pld alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol 2010;28(18s Suppl):abstract LBA5012b
   Google Scholar
• Jelovac D, Armstrong DK. Role of farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des 2012;18(25):3812-15
   PubMed Web of Science ®Google Scholar
• Morphotek announces top-line results of a phase iii study of farletuzumab in patients with relapsed platinum-sensitive epithelial ovarian cancer. 2013. Available from: http://www.morphotek.com/news-events/News-Archive/2013-News/Morphotek-Announces-Top-Line-Results-of-A-Phase-II.aspx
   Google Scholar